Publication Name	World Journal of Hepatology
Manuscript ID	66856
Country	Australia

Received	2021-04-07 20:28
Peer-Review Started	2021-04-07 20:31
To Make the First Decision
Return for Revision	2021-06-15 22:06
Revised	2021-06-27 14:02
Second Decision	2021-08-09 02:29
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-08-09 06:25
Articles in Press	2021-08-09 06:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-09-15 02:42
Publish the Manuscript Online	2021-09-22 08:09

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
Manuscript Source	Invited Manuscript
All Author List	Ankit Jain, Shivakumar Chitturi, Geoffrey Peters and Desmond Yip
ORCID	Author(s) ORCID Number Ankit Jain http://orcid.org/0000-0001-9498-380X Shivakumar Chitturi http://orcid.org/0000-0002-2367-9859 Geoffrey Peters http://orcid.org/0000-0003-2869-289X Desmond Yip http://orcid.org/0000-0002-2806-2401
Funding Agency and Grant Number
Corresponding Author	Ankit Jain, DNB, FRACP, MBBS, MD, Staff Physician, Department of Medical Oncology, The Canberra Hospital, Building 19, Level 5, Yamba Drive, Garran 2606, ACT, Australia. ankit.jain@anu.edu.au
Key Words	Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Immunotherapy; Child Pugh cirrhosis; Anti-angiogenic therapy
Core Tip	There are several articles about the role of atezolizumab and bevacizumab combination in advanced unresectable hepatocellular carcinoma. However, this mini review focuses on practical issues for clinicians using this combination in hepatocellular carcinoma (HCC) patients with focus on indications, data from recent trials, criteria’s for selection of appropriate patients for this combination, sequencing strategies, overlapping toxicities, issues with Child Pugh B cirrhosis patients, future role in adjuvant settings and dealing with special subset of HCC population.
Publish Date	2021-09-22 08:09
Citation	Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142
URL	https://www.wjgnet.com/1948-5182/full/v13/i9/1132.htm
DOI	https://dx.doi.org/10.4254/wjh.v13.i9.1132

Full Article (PDF)	WJH-13-1132.pdf
Full Article (Word)	WJH-13-1132.docx
Manuscript File	66856_Auto_Edited-JPY.docx
Answering Reviewers	66856-Answering reviewers.pdf
Audio Core Tip	66856-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	66856-Conflict-of-interest statement.pdf
Copyright License Agreement	66856-Copyright license agreement.pdf
Supplementary Material	66856-Supplementary material.pdf
Peer-review Report	66856-Peer-review(s).pdf
Scientific Misconduct Check	66856-Scientific misconduct check.pdf
Scientific Editor Work List	66856-Scientific editor work list.pdf